Symptomatic aortic stenosis (AS) is an increasing phenomenon as more adults live longer. The gold standard for treating AS is surgical aortic valve replacement (SAVR). Frequently, as older individuals with AS often have multiple comorbidities, a SAVR is determined to be too high risk. Therefore, a less invasive treatment option is available, namely a transcatheter aortic valve implantation (TAVI) or transcatheter aortic valve replacement (TAVR). Such biomedical procedures have encouraged life extension and the decision to intervene commonplace with the aging population. Without an intervention, significant debilitating symptoms affect a person's quality of life (QoL). Multiple quantitative studies evaluating QoL before and after a TAVI have been performed. However QoL has multiple attributes and is not a single construct. By limiting practice to these defined QoL measures, we exclude the human experience and what values individuals describe as important to them. The dilemma in the present medical model is influenced by two paradigms, evidence based medicine and patient centered medicine. Some people opt not to have a TAVI. This study aims to understand what it is like living with aortic stenosis as perceived by the participant and to gain a more meaningful understanding of why some individuals with AS choose not to have this procedure performed. Using a convenience sample of patients who declined a TAVI, a telephone interview with the person focused on their perceived QoL and the implications determining not to pursue a TAVI. In this qualitative phenomenological design, open-ended questions included: 1) What is it like to live with Aortic Stenosis. 2) Why did you choose not to have the TAVI? Interviews will explore emerging themes. Advanced practice nurses are in ideal positions for performing research to gain greater insight on the complexity of people's health choices. As the incidence of AS occurs more frequently in the increasing aged population, TAVI offers a treatment option for those patients who are symptomatic with AS and are not surgical candidates. However, health care providers should focus on the illness, not the disease, and explore the patients' biopsychosocial values with their medical needs. The information gathered in this study will help guide heath care providers with offering holistic health care incorporating both paradigms of evidence based practice and patient centered medicine options on treatment for people with symptomatic AS.

Hybrid powertrains that use compressed air to help power a vehicle could dramatically improve the fuel economy, particularly in cities and urban areas where the traffic conditions involve a lot of starts and stops. In such conditions, a large amount of fuel is needed to accelerate the vehicle, and much of this is converted to heat in brake friction during decelerations. Capturing, storing and reusing this braking energy to produce additional power can therefore improve fuel efficiency. In this study, three approaches towards air hybrid powertrains are proposed and analyzed. In the first approach, an energy recovery valve or two shut-off valves connected to a convenient access hole on the engine cylinder is proposed to enable the cylinder to operate as a regenerative compressor and/or expander when required. In the second approach, one of the exhaust valves in an engine equipped with a Fully Variable Valve Actuation (FVVA) system is pneumatically or hydraulically operated as a dedicated gas transfer valve connected to an air reservoir. The third approach combines the advantages of the conventional valvetrain’s simplicity with emerging production technologies. In order to achieve this, two well established technologies are used in addition to valve deactivation; Variable Valve Timing (VVT) and/or Cam Profile Switching (CPS). Provided that a conventional, camshaft-operated variable valvetrain is used, the need of adopting fully variable valve actuation is eliminated and thus only minor modifications to the engine architecture are required. The aforementioned concepts are described in details. Some basic principles of their operation are also discussed in order to provide a better understanding on how fuel economy is achieved by means of engine hybridization and regenerative braking. Both experimental and computational results are presented and compared. Finally, a vehicle and driveline model, which simulates the operation of a typical passenger vehicle in urban driving conditions and predicts the efficiency of the energy regeneration, has been set up and used to study the effects of the application of each air hybrid concept on the vehicle’s energy usage throughout the New European Driving Cycle (NEDC) and the 10-15 driving cycle. The results have shown that each concept involves the optimization of valve timing for the best regenerative energy recovery and its subsequent usage. For the modelled vehicle, it has been shown that any of the three concept engines is capable of providing more braking power than needed during every deceleration and braking process, especially throughout the urban driving part of each cycle. The recovered braking energy in the form of compressed air has proved to be always sufficient to start the engine, if stop-and-start engine operation strategy is to be adopted.

Desde a sua invenção, o motor a combustão interna sofreu significantes evoluções, como redução do consumo de combustível, aumento da sua potência e durabilidade a um menor custo. Outros setores também evoluíram, como a busca por alternativas de combustível, tendo como exemplo o etanol hidratado combustível, que trouxe vantagens tais como maior desempenho e menor emissão de poluentes, porém com solicitações mecânicas, térmicas e termomecânicas mais severas. Sua menor lubricidade, quando comparada a da gasolina tipo C também intensificou o desgaste no par tribológico válvula e sede de válvula. Neste trabalho foram analisados diversos pares de válvulas e sedes de válvulas provenientes de quatro motores pós teste, sendo dois deles de mesma especificação técnica e submetidos às mesmas condições de ensaio, variando somente o combustível utilizado (etanol hidratado combustível e gasolina comum tipo C). A topografia da superfície de contato foi avaliada através de exames das superfícies com lupa estereoscópica, microscópio eletrônico de varredura e perfilômetro óptico a fim de identificar os danos encontrados. Ao término das análises foi realizada a comparação dos danos encontrados entre a superfície de contato das válvulas e sedes do motor que operou com etanol hidratado combustível e gasolina comum tipo C, de forma a evidenciar as diferenças proporcionadas pelos combustíveis. Este trabalho faz parte do \"Consórcio de P&D e Desafios Tribológicos em Motores Flex-Fuel\" patrocinado pela FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo) com participação da indústria automotiva, para identificar os modos de desgaste atuantes. / Since its invention the internal combustion engine presented significant improvements like lower fuel consumption, higher power and durability increase at reduced costs. Other industries sectors did also improve as the search for new alternative fuels such as hydrated ethanol fuel which brought advantages like higher performance with lower pollutant emissions, although with it came more severe mechanical, thermal and thermo-mechanic stresses. Ethanol lower lubricity when compared to type C gasolines did also increase the valve/ valve seat insert wear. This study presents the results of contact surface analysis of several pairs valve/ valve seat insert from four engines after test being two of them of same technical specification and submitted to the same test cycle with only difference their fuel (hydrated ethanol and regular type C gasoline). The contact surface topography was evaluated through surface exams using optical microscopy, scanning electron microscope and non-contact profiler, to evaluate damages. At the end of analysis, a comparison between valves and valve seats from the engines that operated with hydrated ethanol and regular type C gasoline in order to put in evidence the damage difference provided by the fuels. This study is part of \"Consórcio de P&D e Desafios Tribológicos em Motores Flex-Fuel\", sponsored by FAPESP (\"Fundação de Amparo à Pesquisa do Estado de São Paulo\") with participation of automotive industries, to characterize the existent wear.

Les forces mécaniques dirigeant la valvulogénèse sont mal connues. Chez le poisson zèbre, le flux induit l’expression du facteur de transcription klf2a de façon endothéliale spécifique afin d’initier ce processus. Nous nous sommes intéressés aux mécanismes moléculaires activés par le flux et aboutissant à la formation des valves cardiaques. En altérant et modifiant le pattern fluidique, nous avons observé le rôle des forces engendrées par le flux pour le contrôle de l’expression de klf2a ainsi que du nombre de cellules endocardiques. Nous avons ensuite regardé les divers mécanosenseurs pouvant intervenir lors de ce processus. Ainsi nous avons mis à jour la présence de cils dans l’endocarde et fait la relation entre les canaux membranaires TRPP2 et TRPV4, la présence de calcium intracellulaire dans les cellules endocardiques et la voie moléculaire PKC-PKD2-HDAC5, composants nécessaires à l’expression du gène klf2a en réponse au flux. Ces données nous permettent de suggérer le rôle de TRPP2, TRPV4 et la voie moléculaire récemment découverte, PKC-PKD2-HDAC5 dans la formation valvulaire dépendante de klf2a. / Mechanical forces that dictate valve formation are not well understood. In zebrafish, blood flow induces expression of the transcription factor klf2a in a specific subset of endocardial cells that will go on to form functional valves. We aimed to identify the molecular mechanisms activating this flow-induced valve formation. By altering and modifying blood flow patterns, we observed that flow-mediated forces are necessary to control early klf2a expression and endocardial cell numbers. We then looked at different mechanosensors operating at early stages of valve development. Using in vivo labelling, we identified primary cilia in the endocardium and showed that the membrane channels TRPP2 and TRPV4 increase intracellular calcium which activates a PKC-PKD2-HDAC5 pathway necessary for klf2a expression in response to flow. Together these data suggest a role for TRPV4, TRPP2 and the recently described PKC-PKD2-HDAC5 signalling pathway in klf2a-mediated valvulogenesis.

"On-off control of hydraulic circuits enables significant improvements in efficiency compared with throttling valve control. A key enabling technology to on-off control is an efficient high speed on-off valve. This project aims to design an on-off hydraulic valve that minimizes input power requirements and increases operating frequency over existing technology by utilizing a continuously rotating valve design. This is accomplished through use of spinning port discs which chop the flow into pulses, with the relative phase between these discs determining the pulse duration. A mathematical model for determining system efficiency is developed with a focus on the throttling, leakage, compressibility, and viscous friction power losses of the valve. Parameters affecting these losses were optimized to produce the most efficient design under the chosen disc-style architecture. Using these optimum parameter values, a first generation prototype valve was developed and experimental data collected. The experimental valve matched predicted output pressure and flows well, but suffered from larger than expected torque requirements and leakage, resulting in a maximum efficiency of 38% at 1.0 duty ratio. Also, due to motor limitations, the valve was only able to achieve a 64Hz switching frequency versus the designed 100Hz frequency. Future design iterations will need to focus on controlling leakage, hydrodynamically balancing the spinning port disc axially to reduce torque requirements, developing a computational fluid dynamics model to gain further insight into the workings of the valve, and creating a control methodology for single and multiple high speed valves."

O expressivo número de brasileiros que necessitam correção anatômica da estenose valvar aórtica acentuada e que não realizam cirurgia de substituição valvar devido ao risco proibitivo justifica a necessidade de investigação, tanto da efetividade no cenário clínico real quanto dos custos impostos ao Sistema Único de Saúde e aos planos de saúde suplementar brasileiros pela incorporação do implante transcateter de valva aórtica, que tem se demonstrado efetivo mas oneroso, internacionalmente. No primeiro artigo da tese, avaliaram-se os desfechos intra-hospitalares, a sobrevida e o reembolso pela internação hospitalar de 41 pacientes com idade média de 78,7 ± 6,3 anos, estenose valvar aórtica acentuada, com recusa cirúrgica e decisão multidisciplinar por tratamento transcateter entre outubro de 2010 e outubro de 2015. Os sujeitos foram seguidos prospectivamente por um período mediano de 15,2 (4,5 – 25,6) meses e a sobrevida estimada em 1 e 2 anos foi de 73,2% e 64,1%, respectivamente. Identificou-se que hipertensão pulmonar e revascularização miocárdica cirúrgica prévia estavam independentemente associadas à menor sobrevida. O valor mediano reembolsado pelos pacientes atendidos pelo Sistema Único de Saúde foi R$ 108.634,34 (101.051,05 – 127.255,27) e R$ 115.126,77 (94.603,21 – 132.603,01) para aqueles internados por planos de saúde suplementar ou particulares, sendo o respectivo valor mediano reembolsado pela prótese valvar de R$ 82.000,00 (82.000,00 – 95.450,00) e 84.050,00 (75.000,00 – 92.400,00) Em um grupo de 585 procedimentos de troca valvar aórtica cirúrgica em indivíduos com idade ≥ 60 anos, realizados entre janeiro de 2010 e dezembro de 2015 na mesma instituição, a mortalidade intra-hospitalar estava associada à idade e foi de 5,9% naqueles com idade entre 60 e 70 anos, 10,8% entre 70 e 80 anos e de 22,2% ≥ 80 anos. O reembolso mediano foi de R$ 14.035,96 (11.956,11 – 16.644,90) para os internados pelo Sistema único de Saúde e R$ 20.273,97 (15.358.03 – 32.815,49) pelos planos de saúde suplementar ou particulares. No segundo artigo da tese, identificou-se que do total de 819 pacientes consecutivamente incluídos no Registro Brasileiro de Implante de Bioprótese Aórtica por Cateter entre janeiro de 2008 e outubro de 2015, 15 (1,8%) sofreram perfuração do ventrículo esquerdo. Os pacientes que apresentaram perfuração eram mais idosos (85,4 ± 6,3 vs. 81,5 ± 7,3 anos, p=0,038), predominantemente mulheres (80,0% vs. 50,5%, p=0,024), apresentavam maior fração de ejeção (67,3 ± 7,8% vs. 58,6 ± 15,0%, p=0,001), menor massa ventricular esquerda (203,9 ± 47,1g vs. 247,6 ± 78,7g, p=0,039) e menor altura do tronco da coronária esquerda (11,2 ± 5,4mm vs. 14,0 ± 3,3mm, p=0,034). Os preditores independentes de perfuração do ventrículo esquerdo foram idade e fração de ejeção. No terceiro artigo, descreve-se um caso de ablação septal para tratamento de miocardiopatia hipertrófica obstrutiva assimétrica para posterior implante transcateter de valva aórtica, sugerindo que esta seja uma estratégia factível quando da concomitância dessas duas condições Em conclusão, os desfechos do tratamento transcateter da estenose valvar aórtica acentuada em pacientes inoperáveis são compatíveis com aqueles do cenário idealizado dos ensaios clínicos randomizados, apesar de estarem associados a custos maiores que os anteriormente estimados por painéis de especialistas. O tratamento cirúrgico, por sua vez, apresentou mortalidade maior que aquela idealizada ou relatada como usual. A hipercinesia do ventrículo esquerdo pode favorecer o trauma determinado pelo guia metálico, posicionado em seu interior para realização do procedimento, estando a fração de ejeção independentemente associada à chance de perfuração. Ainda, a ablação septal por álcool eletiva, anterior ao implante transcateter da valva aórtica, é uma abordagem factível para pacientes com hipertrofia ventricular esquerda assimétrica obstrutiva associada à estenose valvar aórtica. / The expressive number of Brazilians who require an anatomic correction for severe aortic valve stenosis and who do not undergo valvar replacement surgery due to prohibitive risk justifies the need to investigate both the effectiveness in the real clinical scenario and the costs imposed to the Public Health System and the Supplementary Health System for the incorporation of the transcatheter aortic valve implantation, which has been shown to be effective but onerous, internationally. In the first article of the thesis, the in-hospital outcomes, long-term survival and reimbursement for 41 patients, with a mean age of 78.7 ± 6.3 years, sever aortic valve stenosis, with surgical refusal and multidisciplinary decision for transcatheter treatment, between October 2010 and October 2015 are described. Subjects were prospectively followed for a median period of 15.2 (4.5 - 25.6) months and the estimated survival at 1 and 2 years was 73.2% and 64.1%, respectively. It was identified that pulmonary hypertension and previous coronary artery bypass grafting were independently associated with lower survival. Median reimbursed values by the Public Health System was R$ 108,634.34 (101,051.05 - 127,255.27) and by supplementary health plans was R$ 115,126.77 (94,603.21 - 132,603.01). The respective median values reimbursed for the valve prosthesis was R$ 82,000.00 (82,000.00 - 95,450.00) and 84,050.00 (75,000.00 - 92,400.00) In a group of 585 surgical aortic valve replacement procedures in subjects aged ≥ 60 years, performed between January 2010 and December 2015 in the same institution, in-hospital mortality was associated with age and was 5.9% in those with age between 60 and 70 years, 10.8% between 70 and 80 years and 22.2% in ≥ 80 years. The median reimbursement was R$ 14,035.96 (11,956.11 - 16,644.90) for those hospitalized by the Public Health System and R$ 20,273.97 (15,358.03 - 32,815.49) by supplementary or private health plans. In the second article of the thesis, it was identified that of the total of 819 patients consecutively included in the Brazilian Registry of Aortic Bioprosthesis Implantation by Catheter (RIBAC) between January 2008 and October 2015, 15 (1.8%) suffered perforation of the left ventricle. Patients with perforation were older (85.4 ± 6.3 vs. 81.5 ± 7.3 years, p=0.038), predominantly women (80.0% vs. 50.5%, p=0.024), had a higher ejection fraction (67.3 ± 7.8% vs. 58.6 ± 15.0%, p=0.001), lower left ventricular mass (203.9 ± 47.1g vs. 247.6 ± 78, 7g, p=0.039) and shorter distance between the aortic annulus and the left main coronary artery ostium (11.2 ± 5.4mm vs. 14.0 ± 3.3mm, p=0.034). The independent predictors of left ventricular perforation were age and ejection fraction. In the third article, a case of septal ablation was described for the treatment of asymmetric obstructive hypertrophic cardiomyopathy for posterior transcatheter aortic valve implantation, suggesting that this is a feasible strategy when these two conditions are concomitant In conclusion, the outcomes of transcatheter treatment of severe aortic stenosis in inoperable patients are compatible with those in the ideal scenario of randomized clinical trials, although they are associated with higher costs than previously estimated by expert panels. Surgical treatment, on the other hand, presented higher mortality than that idealized or reported as usual. The left ventricle hyperkinesia may favor the trauma determined by the metallic guide, positioned inside it to perform the procedure, the ejection fraction being independently associated with the chance of perforation. Furthermore, elective alcohol septal ablation, prior to transcatheter aortic valve implantation, is a feasible approach for patients with obstructive asymmetric left ventricular hypertrophy associated with aortic valve stenosis.

O objetivo deste trabalho foi estudar e comparar a valva mitral e a valva aórtica e em corações com cardiomiopatia dilatada (CMD) de etiologia isquêmica e idiopática, em relação aos corações humanos normais, buscando identificar variações que possam auxiliar em diagnósticos por imagem e para o tratamento cirúrgico das mesmas. Este estudo analisou 22 corações normais, 15 corações dilatados de etiologia isquêmica e 15 corações dilatados de etiologia idiopática, fixados em formaldeído a 10%. Foram obtidas medidas por meio de fotografias digitais dos corações e, posteriormente, utilizando-se software, foram analisados as distâncias e os perímetros da valva mitral e da valva aórtica, que foram comparadas por meio de testes estatísticos. Nos corações normais, a área da valva mitral foi de 5,44 ± 0,82 cm2 e o perímetro de 8,91 ± 0,57 cm, e nos corações com CMD de etiologia isquêmica e idiopática, a área foi de, respectivamente, 7,38 ± 1,76 cm2 e 7,03 ± 1,44 cm2, e o perímetro foi de, respectivamente, 10,41 ± 1,37 cm e 9,97 ± 1,23 cm. O perímetro de inserção da cúspide anterior da valva mitral, nos corações normais, foi de 3,68 ± 0,52 cm e nos corações com CMD de etiologia isquêmica e idiopática foi de, respectivamente, 3,99 ± 0,86 cm e 3,62 ± 0,78 cm. A menor distância perimetral entre os trígonos fibrosos (porção fibrosa), nos corações normais, foi de 2,06 ± 0,26 cm e nos corações com CMD de etiologia isquêmica e idiopática foi de, respectivamente, 2,64 ± 0,37 cm e 2,34 ± 0,37 cm. Nos corações normais, a área da valva aórtica foi de 3,46 ± 0,66 cm2 e o perímetro de 6,83 ± 0,66 cm. Nos corações com CMD de etiologia isquêmica e idiopática, a área da valva aórtica foi de, respectivamente, 5,22 ± 1,53 cm2 e 3,44 ± 1,33 cm2, e o perímetro de, respectivamente, 8,26 ± 1,24 cm e 6,82 ± 1,37 cm. Nos casos de CMD idiopática e isquêmica, a valva mitral apresentava-se aumentada, tanto na sua área e em seu perímetro, quanto na maior e na menor distância perimetral entre os trígonos fibrosos. Em relação à valva aórtica, apenas nos corações com CMD isquêmica houve aumento estatisticamente significante em sua área e em seu perímetro, enquanto que nos corações com CMD idiopática não houve diferença quando comparados aos corações normais. Há manutenção da proporcionalidade, dos corações normais para os com CMD idiopática e isquêmica, das distâncias entre os trígonos fibrosos. Há evidência de que o aumento da valva mitral e da valva aórtica, quando ocorrem na CMD, se dão de forma independente. / The objective of this work was to study and to compare mitral valve as well as aortic valve in the ischemic and idiopathic dilated cardiomyopathy (CMD) in relation to the normal hearts, searching to identify variations that can assist in diagnostic for image and for the surgical treatment of the same ones. This study it analyzed 22 normal hearts, 15 dilated hearts of ischemic etiology and 15 dilated hearts of idiopathic etiology, fixed in formaldehyde 10%. They had been gotten measured through digitalized photographs of the hearts, and, through software, the distances and perimeters of the mitral valve and of the aortic valve had been analyzed, that later they had been compared through statistical tests. In the normal hearts, the area the mitral valve was 5.44 ± 0.82 cm2 and the perimeter of 8.91 ± 0.57 cm. In the hearts with ischemic and idiopathic CMD the area of the mitral valve were, respectively, 7.38 ± 1.76 cm2 and 7.03 ± 1.44 cm2, and to the perimeter it were, respectively, 10.41 ± 1.37 cm and 9.97 ± 1.23 cm. The perimeter of insertion of anterior cusp of mitral valve in the normal hearts was 3.68 ± 0.52 cm, in the hearts with ischemic and idiopathic CMD were, respectively, 3.99 ± 0.86 cm and 3.62 ± 0.78 cm. The lesser length enter the fibrous trigones (fibrous portion) in the normal hearts was 2.06 ± 0.26 cm and in the hearts with ischemic and idiopathic CMD were, respectively, 2.64 ± 0.37 cm and 2.34 ± 0.37 cm In the normal hearts the area of aortic valve was 3.46 ± 0.66 cm2 and the perimeter of 6.83 ± 0.66 cm. In the hearts with ischemic and idiopathic CMD the area of aortic valve were, respectively, 5.22 ± 1.53 cm2 and 3.44 ± 1.33 cm2, and the perimeter of, respectively, 8.26 ± 1.24 cm and 6.82 ± 1.37 cm. In the cases of idiopathic and ischemic CMD, mitral valve is presented increased, as much in its area and its perimeter, how much in the greater and the lesser perimetral distance between the fibrous trigones. In relation to aortic valve, only in the hearts with Ischemic CMD it had significant statistic increase in its area and its perimeter, whereas in the hearts with Idiopathic CMD it did not have difference when compared with the normal hearts. It has maintenance of the proportionality, the normal hearts for the ones with idiopathic and ischemic CMD, of the distances between the fibrous trigones. It has evidence of that the increase of mitral valve and aortic valve, when they occur in the CMD, occurs of independent form.

BACKGROUND: Calcific aortic valve disease (CAVD) is the most prevalent heart valve disease in the developed world, claiming almost 17,000 deaths annually in the United States. The lack of noninvasive therapeutics to slow or halt the disease warrants the need for further understanding of the pathobiological mechanisms of CAVD. A tri-laminar structure of aortic valve determines the biomechanical properties of its leaflets. Valvular endothelial cells (VECs) and interstitial cells (VICs) are responsible for valve structural integrity. Traditional two-dimensional culture conditions spontaneously activate the pathological differentiation of VICs making in vitro studies challenging. A monolayered three-dimensional (3D) hydrogel platform was recently developed as a novel in vitro culture system to study the phenotypic changes of VICs leading to microcalcification (early stages of calcification). This system, however, did not fully recapitulate the microenvironment of native valve tissues because of the lack of individual layer representations and endothelial coverage. Bioprinting technology, which allows precise and integrated positioning of cells, matrix, and biomolecules, may provide an innovative approach toward building a more biologically relevant 3D culture platform. OBJECTIVE: This study aims to lay the groundwork for building a multilayered 3D-bioprinted culture platform to study CAVD by first validating the use of bioprinting in monolayered cell-laden 3D hydrogel constructs. METHODS: Human VICs were isolated from patients undergoing valve replacement surgeries at Brigham and Women’s Hospital (Boston, MA) according to Institutional Review Board (IRB) protocols. VICs were expanded in culture medium containing growth factors for up to 6 passages and then encapsulated in hydrogels using 3D bioprinting technology. After encapsulation, VIC-laden 3D constructs were cultured in either normal or osteogenic conditions for 21 days. Microcalcification, cell proliferation, and cell apoptosis were evaluated using fluorescent staining and confocal microscopy. Results were compared with results from VIC-laden hydrogels made manually. RESULTS: An increase in microcalcification was observed throughout bioprinted VIC-laden hydrogel constructs cultured in osteogenic conditions for 21 days, whereas normal conditions developed negligible calcification signals. Cell proliferation and apoptosis were not significantly different between normal and osteogenic groups in bioprinted hydrogels. Cell-free hydrogels did not exhibit any microcalcification. Overall, bioprinted hydrogels showed less nonspecific background staining than handmade hydrogels, thus providing a better means for quantitative assessments of 3D culture platforms. CONCLUSION: Based on bioprinting technology, an improved monolayered cell-laden hydrogel platform was successfully established as a first step toward building an in vitro multilayered disease model for studying the pathobiological mechanisms of CAVD. The results in this study were consistent with current literature that proposes calcification as a cell-dependent, apoptotic-independent, and proliferation-independent pathway. / 2019-07-13T00:00:00Z

Le rétrécissement aortique calcifié dégénératif (RAC) représente la principale pathologie valvulaire cardiaque dans les pays occidentaux (2% à 7% de la population après 65 ans). Il n’existe, à ce jour, aucun traitement médical qui permette de stopper ou de prévenir la progression du RAC. Le seul traitement du RAC sévère est le remplacement valvulaire aortique chirurgical ou par cathétérisme (TAVI) en cas de symptômes (dyspnée,douleur thoracique ou syncope), de dysfonction ventriculaire gauche (FEVG<50%) ou de mauvaise tolérance fonctionnelle lors d’un test d’effort. À l’inverse, la prise en charge des patients asymptomatiques avec un RAC sévère est controversée devant le risque de mort subite ou de détérioration myocardique irréversible sans traitement et le risque de la chirurgie cardiaque prophylactique et des complications prothétiques. De plus, le RAC intéresse une population de plus en plus âgée où la présence de symptômes peut être difficilement évaluable et où s’associent des facteurs de risques et des comorbidités cardiovasculaires rendant la stratégie clinique de plus en plus compliquée. Enfin, il semble que parmi les patients avec un RAC serré asymptomatique, certains sont à plus haut risque d’évènements et bénéficieraient peut être d’une chirurgie plus précoce. L’identification de marqueurs de progression et pronostiques objectifs dans ce sous-groupe de patients constitue donc un enjeu très important. / Aortic valve stenosis (AS) is the most common valvular heart disease in Westerncountries AS (2%–7% of the population after 65 years old) for which valve replacement is theonly curative treatment. Current guidelines recommend surgery in patients with severe ASand either symptoms or left ventricular systolic dysfunction (LVEF<50%). However,treatment of asymptomatic patients remains controversial due, on the one side, to the riskof sudden death without preceding symptoms and irreversible myocardial dysfunction and,on the other side, to the risk of surgery and prosthetic valve complications. Identifyingsubsets of asymptomatic AS patients with preserved left ventricular ejection fraction whomay benefit from early or prophylactic surgery is therefore a critical clinical challenge.

Experiments described in this thesis address the pathogenesis of aortic valve sclerosis/stenosis using a bench to bedside approach. In particular, the thesis begins with development of a technique using ultrasonic backscatter analyses to quantitate the early stages of aortic stenosis. Subsequent chapters utilized this methodology to quantitate aortic valve structural changes in a model and intervention study of aortic stenosis in rabbits. The last chapters are human studies designed to identify factors associated with presence of aortic sclerosis/stenosis; with particular interest in potential association of endothelial dysfunction/inflammation/platelet aggregation with abnormal aortic valve structure quantitated by ultrasonic backscatter. In Chapter 1 (Introduction) the relevant literature is reviewed. Development of ultrasonic backscatter to quantitate aortic sclerosis (Chapter 2) Aortic valve sclerosis (ASc) is detected when there is visual assessment of focal increases in echogenicity of the aortic valve most commonly assessed by echocardiography. However, there is no previously described method to quantitate degree of aortic valve structural abnormality as ASc is not associated with marked hemodynamic obstruction quantifiable by Doppler echocardiography. The current study used ultrasonic backscatter to quantitate aortic valve structural abnormality in patients assessed as having ASc based on valve appearances, compared to young healthy volunteers with normal aortic valves. The results of the study indicate: 1) that the mean levels of aortic valve backscatter in ASc patients are approximately 60% greater than in young healthy volunteers (ie aortic valve backscatter scores ≥ 16dB are not consistent with normal aortic valve structure), 2) ultrasonic backscatter scores in ASc patients are directly correlated with subjective scoring of sclerosis and with a positive trend with transvalvular pressure gradients in patients with mild-moderate aortic stenosis, and most importantly, 3) ultrasonic backscatter is a reproducible technique, with mean differences between estimates based on repeat echocardiograms of 2.3 ± 1.7 (9.1%). These results indicate that ultrasonic backscatter could be used as a quantitative measure of aortic valve structural abnormality in epidemiology and for examination of interventions. In vivo studies Development of an animal model of aortic stenosis with vitamin D2 (Chapter 3) The aim of the study was to develop an appropriate animal model for AS. The study used vitamin D2 alone at 25,000IU/4 days weekly (vit-D2) for 8 weeks to induce AS in rabbits. Results showed that: 1) rabbits in the vit-D2 group had significantly increased in transvalvular velocity and pressure gradients compared to rabbits in the control group (normal chow + drinking water); this was consistent for aortic valve ultrasonic backscatter scores; 2) aortic valve immunohistochemistry/histology showed marked calcification, neutral lipids, macrophage, and leukocyte infiltrations for rabbits in the vit- D2 group (ie consistent with histology of human AS); 3) significant elevation of asymmetric dimethylarginine (ADMA) concentrations in the vit-D2 group occurred compared to controls over the 8 weeks treatment period; the change in ADMA concentrations correlated significantly with the change in transvalvular pressure gradients for rabbits in the vit-D2 group; 4) rabbits in the vit-D2 group had significantly impaired endothelium-dependent acetylcholine-induced aortic relaxation, and this effect was completely abolished by the nitric oxide synthase inhibitor (L-NAME); 5) the addition of 0.5% cholesterol-supplemented diet to the vitamin D2 regimen did not accentuate the development of AS. Thus, treatment with vitamin D2 at 25,000IU/4 days weekly for 8 weeks significantly induced AS with similar aortic valve pathology to that of human AS; therefore, the model is suitable for use in examining potential therapeutic interventions in AS. Effects of ramipril on development of AS in rabbits (Chapter 4) Using this animal model, this study aimed to examine the effects of the angiotensinconverting enzyme inhibitor (ACEi) ramipril on development of AS. Rabbits (n=28) treated for 8 weeks were divided into 2 groups: (a) vitamin D2 alone (n=10) (normal chow + 25,000IU vitamin D2 in drinking water); (b) vitamin D2/Ramipril (n=12) (normal chow+25,000IU vitamin D2/Ramipril (0.5mg/kg) in drinking water). Six further rabbits constituted a normal reference group (no treatment was given). The results for comparisons between vitamin D2/ramipril vs vitamin D2 alone were as follows: 1) ramipril-treated rabbits had significantly less severe hemodynamic obstructions (p<0.05, for both) as assessed by transvalvular velocity, and aortic valve area; with borderline reduction in aortic valve backscatter (p=0.08); 2) ramipril significantly reduced plasma ADMA concentrations; 3) there was improvement in acetylcholine-induced aortic relaxation (p=0.056), with significant improvement in sodium nitroprusside-induced relaxation (p<0.05); 4) there was a strong inverse correlation between acetylcholineinduced aortic relaxation and aortic valve backscatter score (0<0.001), thus providing further evidence of the potential role of nitric oxide in retarding the development of AS in this model. These data provide a strong rationale for the inception of a randomized trial of ACE inhibition as a strategy for limitation of AS progression in humans. Human studies Aortic stenosis is associated with elevated plasma levels of asymmetric dimethylarginine (ADMA) concentrations in humans (Chapter 5). Given the findings that aortic stenosis induced by vitamin D2 in rabbits also caused elevation of plasma ADMA concentrations, a physiological inhibitor of nitric oxide synthase, a mediator and marker of endothelial dysfunction and an indicator of incremental cardiovascular risk. The study sought to determine whether plasma ADMA concentrations are elevated independently of pre-existing coronary risk factors in subjects with at least moderate aortic stenosis (n=42) compared to age-matched patients with normal aortic valves (n=42): as determined both by visual assessment and with aortic valve backscatter scores < 16dB. Results for this study were as follows: 1) plasma ADMA concentrations were not statistically different between the AS and non-AS group (median 0.59 vs 0.54 µmol/L, p=0.13, Mann-Whitney test) on univariate analysis; 2) backward stepwise multiple linear regression showed the presence of AS was a significant predictor of elevated ADMA concentrations (p=0.04, 95% CI =0.001, 0.072). 3) in addition, elevated plasma ADMA concentrations were also associated with history of atrial fibrillation (p=0.009, 95% CI=0.015, 0.100), and negatively associated with creatinine clearance (p=0.01, 95% CI=-0.002, 0.000), and the use of statin therapy (p=0.01, 95% CI=-0.081, -0.011). Therefore, in conclusion, this study found that AS is independently associated with elevation of ADMA concentrations, beyond that implied by “conventional” risk factors for endothelial dysfunction. The clinical status of AS as an incremental marker of cardiovascular risk may reflect ADMA-mediated endothelial dysfunction. Assessment of factors associated with ASc in a random ageing population study (Chapter 6). There have been few clinical studies of factors associated with ASc. Previous population studies have established that ASc is an independent correlate of incremental risk of coronary events. Having established that patients with AS have increased plasma ADMA concentrations (Chapter 5), it was now aimed to determine whether subjects with increased aortic valve backscatter scores (ASc) also have other markers of endothelial dysfunction/NO effects, independent of preexisting coronary risk factors. The study was designed to identify such anomalies, if they existed, on an incremental basis to other putative correlates of ASc, including coronary risk factors, renal dysfunction and vitamin D levels. Random selected subjects (n=253) aged between 51 to 77 years were evaluated. All patients underwent transthoracic echocardiography examination; aortic valve ultrasonic backscatter score (AVBS), was used to quantitate echogenicity of the aortic valve. Conventional coronary risk factors were identified on history. Integrity of NO generation/response was assessed via (i) plasma ADMA concentrations; (ii) inhibition of platelet aggregation by the NO donor sodium nitroprusside (SNP); (iii) aortic augmentation index (AIx), a measure of arterial stiffness/wave reflection. All putative correlations with AVBS were examined by univariate and stepwise multiple linear regression analyses. On the basis of echocardiographic appearances, ASc was present in 63 subjects (25.4%); mean AVBS scores was 14.9±4.6dB (SD) vs 11.2±3.9dB (SD) in the presence vs absence of ASc (p<0.001). Univariate analyses revealed that platelet responsiveness to NO was inversely correlated with AVBS (β=-0.16, p=0.02); but [ADMA] and AIx were not. On multiple linear regression, significant correlates of increased AVBS were: (i) advanced age (β=0.21, p=0.003), (ii) low body mass index (β=-0.23, p=0.001); and (iii) impaired platelet responsiveness to NO (β=-0.16, p=0.02). In Chapter 7, the implications of the overall findings in this thesis are discussed in relation to future perspective. / http://proxy.library.adelaide.edu.au/login?url= http://library.adelaide.edu.au/cgi-bin/Pwebrecon.cgi?BBID=1309350 / Thesis(Ph.D.) -- School of Medicine, 2008